Category: Companies

Posted on

Mindset Announces Milestone in New Drug Program with Successful Proof-of-Concept Animal Studies of Its Patent-Pending Psilocybin-Inspired Drug Candidates

Toronto, Ontario–(Newsfile Corp. – February 10, 2021) –  Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (“Mindset” or the “Company“), a drug discovery and development company focused on developing next generation psilocybin-inspired medicines and related technologies, is pleased to announce that several of its proprietary, novel and diverse psychedelic compounds are demonstrating strong potency and efficacy, superior to psilocybin in in vivo proof-of-concept (“PoC“) studies. These PoC results in animal models represent a significant advancement in Mindset’s development of its new psychedelic drug program.

Mindset New Drug Program

Mindset has developed a leading pipeline of diverse patent-pending pre-clinical psilocybin-inspired drug candidates, employing cutting-edge structure-based drug design strategies in order to create novel and patentable optimized psychedelic drug candidates for pharmaceutical use. Mindset’s new drugs are broadly grouped into three “families”.

The first family can further be divided into prodrugs and deuterated analogs of psilocybin. The former has shown rapid metabolism into psilocin with verified efficacy both in vitro and in vivo. The deuterated analogs have shown similar effects as psilocin on receptor binding and function assays and in vivo data indicate similar efficacy to psilocybin with oral bioavailability and central nervous system penetration. This positions this first family of compounds as potential rapid drug development candidates for generic patentable psilocybin.

The second family, which consists of restricted side-chain analogs of psilocybin, show increased potency and efficacy compared to psilocin and psilocybin based on both in vitro and in vivo data, respectively. Certain compounds also show oral bioavailability and are brain penetrant with in vivo pharmacokinetic evidence of shorter duration than psilocybin. This profile positions this second family of compounds for next generation in clinic candidates to support psychedelic-assisted psychotherapy applications and protocols.

The third and final family continues to demonstrate unique and promising in vitro profiles. In particular, certain compounds from the third family show a similar binding profile to the human 5HT2A receptor comparable to that of psilocin’s, but with smaller effect size and a much longer duration of action based on human liver microsome stability data. This profile uniquely positions the third family of compounds for potential microdosing applications, including specialized populations and indications such as pediatric ADHD and Alzheimer’s disease.

The results of these PoC studies indicate that Mindset has several promising psilocybin-inspired drug candidates with differentiated pharmacological properties. Consistency between its in vitro and in vivo studies strongly validates both Mindset’s extensive in vitro drug screening protocols as well as the elegant drug design strategies used by the Mindset scientific team.

James Lanthier, Chief Executive Officer of Mindset, commented “We believe that there will be multiple next generation psychedelic compounds used clinically in treating mental health disorders and that different treatment protocols for various indications will require distinct drug characteristics. It has been the goal of the Company’s new drug discovery program to identify and qualify a rich portfolio of psychedelic drug candidates that demonstrate variations in onset, duration, potency, safety and receptor selectivity. Mindset’s pre-clinical results to date demonstrate significant progress towards this goal, with several promising psychedelic drug candidates exhibiting diverse pharmacological properties”.

Based on further pre-clinical testing, the Company expects shortly to select multiple lead compounds to advance towards investigational new drug-enabling studies in the second half of 2021.

FOR MORE INFORMATION, PLEASE CONTACT:

James Lanthier
Chief Executive Officer
jlanthier@mindsetpharma.com

Jason Atkinson
VP, Corporate Development
jatkinson@mindsetpharma.com

About Mindset Pharma Inc.

Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. Mindset was established to develop next generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several novel families of next generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin along with its own proprietary compounds. www.mindsetpharma.com.

Forward-Looking Information

This news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “would”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Forward-looking information is based on the opinions and estimates of management at the date the information is provided, and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis. The Company undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change, unless required by law. The reader is cautioned not to place undue reliance on forward-looking information.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Posted on

Bright Minds Biosciences Strengthens Scientific Advisory Team to Prepare for Future Growth

VANCOUVER, British Columbia, Feb. 10, 2021 (GLOBE NEWSWIRE) — Bright Minds Biosciences (“Bright Minds” or the “Company”), a biosciences company focused on creating the next generation of psychedelic and related therapies for the treatment of mental health and central nervous system disorders, today announced three additions to its scientific advisory team: John M. McCall, PhD, Senior Advisor; Mark A. Geyer, PhD, Advisor; and Uros Laban, Senior Chemist.

 

“We are delighted to welcome John, Mark and Uros to the Bright Minds team. Their collective research, drug development and patent expertise will undoubtedly help us to advance our programs through the clinical phase and ultimately to market. Bright Minds is committed to designing and delivering psychedelic therapeutics with improved safety and predictability that can address the many unmet medical needs in the mental health and pain management areas. As we expand our cadre of renowned scientific advisors, we look forward to their insights and contributions, and to taking full advantage of the opportunities ahead,” stated Ian McDonald, CEO.

 

John M. McCall, PhD, is Co-Founder, Chairman of the Board and Vice President of Chemistry at ReveraGen BioPharma, a company with a focus on developing therapeutics for Duchenne muscular dystrophy. His expertise includes medicinal biochemistry, steroidal chemistry, risk minimization and strategic planning. Dr. McCall began his career as a medicinal chemist with Upjohn and subsequently held positions with Pharmacia and Pfizer. He was Director of CNS Research with Upjohn, Vice President and Global Head of Chemistry for both Pharmacia and Pharmacia Upjohn and Vice President Research with Pfizer. He has extensive consulting experience via his privately owned PharMac firm, advising National Institutes of Health (“NIH”), academic, and pharmaceutical partners in the translational drug discovery and development areas. Dr. McCall currently chairs a NINDS development team in the spinal muscular atrophy area, serves on boards and scientific advisory boards, consults, participates as a NIH study section member, works with three venture capital funds, and is a partner with the Upjohn Group. Dr. McCall’s Board and Scientific Advisory Board positions include UCB, CeeTox, Synergenics, Psychogenics, Avaant, Deciphera, Lycera, Michigan High Throughput Screening Center, Verseon, CINRG, Reaction Biology, Scripps, AdmetRx, and PharmOptima. Dr. McCall holds 54 U.S. patents and has over 60 refereed publications. Dr. McCall received a PhD in Organic Chemistry from the University of Wisconsin and did his postdoctoral work at Harvard University.

 

Mark A. Geyer, PhD, is Distinguished Professor of Psychiatry and Neurosciences Emeritus at the University of California San Diego (“UCSD”), where he directs the Neuropsychopharmacology Unit of the VISN 22 Veterans Administration Mental Illness Research, Clinical, and Education Center. In 1993, he co-founded the Heffter Research Institute, which pioneered and supported much of the scientific research that has prompted the exploration of psychedelics as potential therapeutics in humans. Dr. Geyer’s research has long focused on developing parallel behavioral paradigms in animals and humans for use in psychiatric drug discovery. He recently co-founded the Psychedelics and Health Research Initiative at UCSD, which is exploring the efficacy of psychedelics in the treatment of pain disorders. Dr. Geyer is respected internationally for his research on the psychophysiology, neurobiology, and pharmacotherapy of schizophrenia and bipolar disorder. He has published more than 470 peer-reviewed papers and over 50 reviews, including many addressing the mechanisms subserving the effects of antipsychotics, psychostimulants, psychedelics, and entactogens. Dr. Geyer received a PhD in Psychology from the University of California San Diego.

 

Uros Laban, PhD, is an experienced medicinal chemist with a breadth of pharmaceutical industry experience across drug development, synthetic chemistry, scale-up, and life sciences. Most recently he was Scientific Consultant-Project Manager at Senai Cimatec, with responsibility for the design and synthesis of novel anti-tuberculosis agents and anticancer remedies from plants. He holds the position of Chief Chemist at Associação Cannab, a company that produces cannabis for patients with debilitating diseases. He is also the Founder of Ewelabs, an international pharmaceutical consultancy, with a focus on strategies for pharmaceutical industry development. Uros honed his skills working in the renowned lab of Professor David Nichols, a pioneer of psychedelic drug discovery. Considered an expert on the future of psychedelics, Dr. Laban has published numerous books and articles and is a frequent speaker at conferences. He received a PhD in medicinal chemistry and did postdoctoral work at Federal University of Rio de Janeiro.

 

About Bright Minds

 

Bright Minds is a pre-clinical biosciences company with a portfolio of compounds designed to precisely target abnormalities in neurocircuitry that lead to dysfunctional behaviors. Bright Minds is focused on developing targeted therapies with the potential to improve the treatment of mental health and neurological disorders through the use of serotonergic compounds, leveraging its world class scientific and drug development expertise to bring forward the next generation of safe and efficacious neuropsychiatry drugs into the clinic. Bright Minds drugs extenuate the therapeutic aspects of psychedelic and other serotonergic compounds while minimizing the side effects, thereby creating superior drugs to first generation compounds, such as psilocybin.

 

Forward-Looking Statements

 

This news release contains forward-looking statements, including statements regarding the date of listing of the Shares and the advancement of the Company’s drug development program, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements.

 

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, and which are described in the Company’s public filings available under its profile at www.sedar.com. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company does not intend to update any of the included forward-looking statements except as required by Canadian securities laws.

 

Investor Contact:
Judy DiClemente
jdiclemente@insitecony.com

 

Originally published on globenewswire.com

Posted on

Mind Cure Announces Closing of $23 Million Bought Deal Offering Including Full Exercise of Over-Allotment Option

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

VANCOUVER, BC, Feb. 10, 2021 /CNW/ – Mind Cure Health Inc. (“Mind Cure” or the “Company”) (CSE: MCUR), a mental health and wellness company with a mission to identify and develop products that ease suffering, increase productivity, and enhance mental health, is pleased to announce that it has closed its previously announced bought deal short form prospectus public offering  (the “Offering”) of units (the “Units”) through a syndicate of underwriters led by Canaccord Genuity Corp. (the “Underwriters”).

Pursuant to the terms of the Offering, the Company issued 38,334,100 Units, including the exercise in full of the Underwriters’ over-allotment option, at a price per Unit of $0.60 for aggregate gross proceeds of $23,000,460. Each Unit consists of one common share (each a “Common Share”) and one-half of one common share purchase warrant of the Company (each whole common share purchase warrant, a “Warrant”). Each Warrant is exercisable to acquire one common share of the Company at an exercise price of C$0.80 per Warrant until February 10, 2026.  If the daily volume weighted average trading price of the Common Shares on the Canadian Securities Exchange (the “CSE”) is greater than C$1.50 per Common Share for the preceding 10 consecutive trading days, the Company shall have the right to accelerate the expiry date of the Warrants to a date that is at least 30 trading days following the date of the Company issuing a press release disclosing such acceleration. The Warrants will be listed for trading on the facilities of the CSE under the symbol “MCUR.WT”. The Company expects the Warrants to commence trading on February 11, 2021.

Kelsey Ramsden, President & CEO of Mind Cure said, “We are delighted to have the trust and support of the investment community as we continue with our mission to advance psychedelic medicine through research into novel and classic psychedelic molecules and therapies as well as pioneering and building iSTRYM, the digital infrastructure necessary to deliver these life-transforming therapies at scale.”

The net proceeds of the Offering will be used by the Company for product research, development and expansion, to further the Company’s technological offerings and capabilities, including the build-out of its iSTRYM application and refinement of its bioinformatics statistical analysis platform PsyCollage, marketing expenditures related to company investor relations and product awareness, as well as working capital and general corporate purposes.

In consideration for their services, the Company paid to the Underwriters a cash commission equal to 6% of the aggregate gross proceeds of the Offering and a reduced commission to 3.0% for proceeds raised from purchasers on a President’s List, for total cash commission in the amount of $1,224,624.60, including gross process raised on exercise of the Over-Allotment Option, and issued to the Underwriters 2,050,041 compensation warrants (the “Compensation Warrants”). Each Compensation Warrant may be exercised to acquire one Common Share (each, a “Compensation Share”) at an exercise price of $0.60 per Compensation Share until February 10, 2026. In addition, the Company paid a corporate finance fee (the “Corporate Finance Fee”) in the amount of $250,000 with 50% of the Corporate Finance Fee paid in cash and 50% of the Corporate Finance Fee paid in Common Shares (the “Corporate Finance Fee Shares”) at a deemed price of $0.60 per Corporate Finance Fee Share for a total of 208,333 Corporate Finance Fee Shares.

Farris LLP acted as Canadian legal advisors to the Company and DLA Piper (Canada) LLP acted as Canadian legal advisors to the Underwriters on the Offering.

ON BEHALF OF THE BOARD OF MIND CURE HEALTH INC.
Kelsey Ramsden
President and Chief Executive Officer

About Mind Cure Health Inc.
Mind Cure Health Inc. (CSE:MCUR) exists as a response to the current mental health crisis and urgent calls for effective treatments. Mind Cure believes in the need to reinvent the mental health care model for patients and practitioners to allow psychedelics to advance into common and accepted care.

Mind Cure is focused on identifying and developing pathways and products that ease suffering, increase productivity, and enhance mental health. Mind Cure is interested in exploring diverse therapeutic areas beyond psychiatry, including digital therapeutics, neuro-supports, and psychedelics, all to improve mental health.

Forward Looking Statements
Certain statements in this news release may constitute “forward-looking information” within the meaning of applicable securities laws (also known as forward-looking statements). Forward-looking information involves known and unknown risks, uncertainties and other factors, and may cause actual results, performance or achievements or industry results, to be materially different from any future results, performance or achievements or industry results expressed or implied by such forward-looking information. Forward-looking information generally can be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases, including references to assumptions. Some of the specific forward-looking information in this news release includes, but is not limited to, statements with respect to: Mind Cure’s intended use of proceeds of the Offering and the listing of the Warrants for trading on the CSE and the timing thereof. Although the forward-looking information contained in this news release is based upon what Mind Cure believes to be reasonable assumptions, it cannot assure investors that actual results will be consistent with such information. Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes.

Forward looking information involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Those risks and uncertainties include, among other things, risks related to: the impacts of the COVID-19 pandemic on the Canadian and global economy, Mind Cure’s industry and its business, which may negatively impact, and may continue to negatively impact, Mind Cure and may materially adversely affect its investments, results of operations, financial condition and Mind Cure’s ability to obtain additional equity or debt financing, and satisfy its financial obligations; general economic conditions; future growth potential; competition for mental health and wellness investments; Mind Cure developing optimized drugs that treat physical and psychological pain and changes in legislation or regulations.

Management believes that the expectations reflected in the forward-looking information contained herein are based upon reasonable assumptions and information currently available; however, management can give no assurance that actual results will be consistent with such forward-looking information. Additional information on the risk factors that could affect Mind Cure can be found under “Risk Factors” in Mind Cure’s final prospectus which is available on SEDAR at www.sedar.com. The forward-looking information contained herein is expressly qualified in its entirety by this cautionary statement. Forward-looking information reflects management’s current beliefs and is based on information currently available to Mind Cure. The forward-looking information is stated as of the date of this news release and Mind Cure assumes no obligation to update or revise such information to reflect new events or circumstances, except as may be required by applicable law.

This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the U.S. Securities Act of 1933 (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons (as defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

SOURCE Mind Cure Health Inc.

For further information: Investor Relations: investors@mindcure.com; 1-888-593-8995

Posted on

Vireo Health Opens Two More Green Goods Cannabis Patient Centers in Twin Cities

— With these new additions, Vireo has successfully executed on its goal to double its number of Minnesota locations to eight by end of 2020 —

MINNEAPOLIS, Feb. 10, 2021 /PRNewswire/ — Vireo Health of Minnesota, LLC (“Vireo” or “the Company”), a subsidiary of Vireo Health International, Inc. (CNSX: VREO, OTCQX: VREOF), today announced the official openings of two new medical cannabis patient centers located in Burnsville, MN and Woodbury, MN. The new locations officially opened for business on December 31, 2020 and expanded the Green Goods brand to eight total locations in Minnesota. The new locations will be the first medical cannabis dispensaries in the cities of Burnsville and Woodbury.

Vireo Logo (PRNewsfoto/Vireo Health, Inc.)

The opening of the new locations comes as Vireo Health of Minnesota also completed a full rebranding of its four existing retail locations throughout the state, now also known as Green Goods. Despite the challenges of 2020, the Company successfully completed these construction projects on time and on budget to effectively meet its own previously announced deadline to augment patient access in the state. Vireo Health of Minnesota now has eight operational Green Goods retail locations in the state.

“We are excited to announce that by launching the new locations in Burnsville and Woodbury, Vireo has fulfilled our promise to Minnesotans to renovate and expand our retail footprint to eight medical cannabis patient centers in the state,” said Chairman and Chief Executive Officer, Dr. Kyle Kingsley. ”Previously, patients in Burnsville and Woodbury had to travel long distances to get their medicine. These new locations will increase access and ensure that all patients in the greater Twin Cities-area will be able to easily access the important treatment and medicine they require.”

The two newest Green Goods cannabis patient centers are located at:

  • Green Goods Burnsville, 14334 Burnhaven Drive, Suite 14334, Burnsville, MN 55306
  • Green Goods Woodbury, 803 Bielenberg Drive, Building F5, Suites 101, Woodbury, MN 55125

Both locations will offer medical cannabis in a variety of consumption formats familiar to most patients, including soft gels capsules, oral solutions, tablets, dissolvable powders, and concentrated cannabis oils. Green Goods will also feature a ‘knowledge bar’ for patients seeking expert information and full-time, onsite pharmacists to help guide patients through their medical cannabis journey.

A Minnesota-based company founded in 2014 by Minneapolis emergency physician Dr. Kyle Kingsley, Vireo is committed to helping Minnesotans who qualify for medical cannabis to better understand and gain access to safe, effective cannabis-based products.

Green Goods locations are designed to create an inviting atmosphere that provides personalized service and wellness programs for patients. The locations will also be used for community engagement events, charitable giving programs, and educational outreach efforts. The rebrand which occurred at the Company’s existing cannabis patient centers in Minneapolis, Bloomington, Rochester, and Moorhead now makes for a more relaxing and engaging environment that helps streamline the process of purchasing medical cannabis products in order to help serve more patients in a timely fashion.

To learn more about Vireo Health of Minnesota and Green Goods retail locations, please visit www.minnesotamedicalsolutions.com.

About Vireo Health International, Inc.

Vireo Health International, Inc. is a physician-led cannabis company focused on bringing the best of technology, science, and engineering to the cannabis industry. Vireo manufactures proprietary, branded cannabis products at environmentally friendly, state-of-the-art cultivation facilities and distributes its products through its growing network of Green Goods™ retail locations and third-party dispensaries. Vireo’s team of more than 400 employees, led by scientists, engineers, and cultivation experts, is focused on efficiency and the creation of best-in-class products, while driving scientific innovation within the cannabis industry and developing meaningful intellectual property. Today, Vireo is licensed to grow and/or process cannabis in nine markets. The Company is operational in five of those markets – including the core markets of Arizona, Maryland, Minnesota, New Mexico, and New York. The Company currently operates 16 dispensaries nationwide and holds additional retail licenses in four markets. For more information about Vireo Health, please visit www.vireohealth.com.

Contact Information 

Media Inquiries 
Albe Zakes
Vice President, Corporate Communications 
albezakes@vireohealth.com
(267) 221-4800

Investor Inquiries 
Sam Gibbons
Vice President, Investor Relations
samgibbons@vireohealth.com
(612) 314-8995

CisionView original content to download multimedia:http://www.prnewswire.com/news-releases/vireo-health-opens-two-more-green-goods-cannabis-patient-centers-in-twin-cities-301225415.html

SOURCE Vireo Health International, Inc.

Posted on

Collaboration with Jamaican retreat provider to conduct observational study

Psyence Group Signs Collaboration Agreement with Leading Jamaican Psilocybin Retreat Provider to Conduct Observational Study

Toronto, Canada/Kingston, Jamaica February 10, 2021 – Psyence Group Inc., through its wholly-owned subsidiary Psyence Therapeutics Corp. (“Psyence”), is pleased to announce it has entered into a Research Collaboration Agreement with MycoMeditations Inc (“MycoMeditations”), a leading psilocybin retreat provider to conduct an observational study of the efficacy of naturally derived psilocybin. The Psyence Group is a leading platform in naturally derived psychedelic therapy and the development and commercialization of related technologies and products. MycoMeditations is the leading global provider of psilocybinassisted therapeutic retreat experiences in Jamaica, with a record of more than 750 guests successfully completing psilocybin-assisted retreats.

“Based on Psyence’s experience, scientific focus, and commitment to Jamaica, we are pleased to partner with Psyence to advance research in the area of psilocybin-assisted therapy,” said Justin Townsend, CEO of MycoMeditations. “We look forward to working with the Psyence team and toward evolving into a centre of excellence in research and therapeutic retreats as well as the future expansion of our offerings in this emerging field,” he added.

The initial retrospective study will investigate a cohort of 30 people who have participated in a MycoMeditations retreat in the past 6 months and had reported suffering psychological trauma prior to their visit (the “Study”). This is the first in a series of studies Psyence intends to carry out that investigate the efficacy of naturally derived compounds in comparison to studies undertaken using synthetically produced molecules.

The Study will be submitted for approval to the Ethics Committee of the Jamaican Ministry of Health, following which, and other relevant consents, the Study will be led by Dr. Tamika Haynes-Robinson, Senior Neuropsychologist at Psyence Group, with initial results anticipated in mid-2021. In support of this work, Dr. Haynes-Robinson attended a MycoMeditations retreat in early January 2021 as an observer in order to inform her study design and to assess areas where there are opportunities for current retreat practices to be augmented through consultation with Psyence’s team of experts via technical, scientific and medical support to bring operations into what is anticipated to be a soon-to-be regulated environment. The Study will utilize MycoMeditations’ existing data combined with Psyence generated data analysis. Following completion of the Study, the parties intend to publish the findings in a peer-reviewed academic journal and other available publication outlets. The findings will inform the commercially licensed cultivation and production work being undertaken by Psyence Production (Pty) Ltd in the Southern African Kingdom of Lesotho (formerly known as Mind Health (Pty) Ltd and a wholly owned subsidiary of Psyence Group
Inc.), pursuant to its federally issued commercial license to cultivate, process, store, and export psilocybin.

Jody Aufrichtig, Co-Founder, President, and CEO, Psyence Group Inc. adds: “This collaboration with MycoMeditations will begin the process of supporting existing groups active in the field of providing psilocybin-based therapies, in their path to enter and participate in the licensed and regulated opportunities and industry being created by industry pioneers. MycoMeditations brings a wealth of practical knowledge and experience that we believe can be of great value to derisking our product development work. We look forward to working with Justin and the MycoMeditations team on generating evidence-based data and
future collaborations.” The Research Collaboration Agreement further serves as an opportunity for the Psyence team of medical and technical professionals to assess the utility of Mycomeditations’ vast database of survey data collected from having led therapeutic psilocybin retreats in Jamaica over the past several years for future research and evaluate its possible use in identifying promising therapeutic pathways and indications. Assuming a positive outcome, the parties
intend to expand their research collaboration with a further prospective study to measure dosing and efficacy within the structure of the retreat-based guided group experience.

About Psyence Group

The Psyence Group sets the global standard for natural psychedelics. The executive team have intenational experience in the business of science and medicine and include global experts in palliative care, neurology, neuroscience and drug development. Psyence has built and operates one of the first federally licensed commercial psilocybin cultivation and production facilities. Psyence is pioneering the use of natural psilocybin for the long-term treatment of psychological trauma and its mental health consequences. Our global footprint operates across multiple legal jurisdictions, through the advanced provision of psychedelic
therapy and experience, as well as market leading functional mushroom brands and product portfolio.

Psyence Contact Information

Lisa-Marie Iannitelli, Investor Relations
Email: ir@psyence.com
Website: www.psyence.com
Media Inquiries: media@psyence.com
General Information: info@psyence.com

About MycoMeditations

MycoMeditations, a world leader in the expanding fields of legal psychedelic therapy and wellness tourism, is driven by its commitment to charting a new way forward for psychological care, therapeutics, research and psilocybin legalization by providing safe, lifeaffirming experiences guided by expert facilitators and mental health professionals.

Media Inquiries: media@MycoMeditations.com

Certain statements in this news release related to Psyence Group Inc and its subsidiaries (collectively “the Company”) are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the approval of the Study and related activities by, and the obtaining of the requisite licences and consents from, the Jamaican regulatory and governmental authorities, the anticipation of the enactment or publication of regulation in the Jamaican psilocybin sector and the optimism surrounding the anticipated positive outcomes of the Study. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.

The Company makes no medical, treatment or health benefit claims about the Company’s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceutical products. The efficacy of such products have not been confirmed by approved research. There is no assurance that the use of psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. The Company has not conducted clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and
safety of potential products do not imply that the Company verified such in clinical trials or that the Company will complete such trials. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company’s performance and operations.

Posted on

Field Trip Health Ltd. Schedules Third Fiscal Quarter 2021 Financial Results Conference Call for Wednesday, February 17, 2021 at 8:00 am ET

TORONTO, Feb. 10, 2021 (GLOBE NEWSWIRE) — Field Trip Health Ltd. (CSE: FTRP, FTRP.WT, OTCQX: FTRPF) (“Field Trip”), a global leader in the development and delivery of psychedelic therapies, announced today that it plans to release financial results for its third fiscal quarter ended December 31, 2020, after market close on Tuesday, February 16, 2021.

The Company will conduct a conference call and webcast to review its results the following day, Wednesday, February 17 at 8:00 am ET. To access the call, please dial 1-877-407-9716 or 1-201-493-6779 and provide conference ID 13715986. A live webcast of the conference call can be accessed via the Events and Presentations section of the Field Trip Health Investor Relations website or via the following link: http://public.viavid.com/index.php?id=143376.

For those unable to attend the live call, a telephonic replay will be available until Wednesday, March 3, 2021. To access the replay of the call dial 1-844-512-2921 or 1-412-317-6671 and provide conference ID 13715986. An archived copy of the webcast will be available on the Events and Presentations section of the Field Trip Health Investor Relations website after the conclusion of the call.

About Field Trip Health Ltd.

Field Trip is the global leader in the development and delivery of psychedelic therapies. With our Field Trip Discovery division leading the development of the next generation of psychedelic molecules and conducting advanced research on plant-based psychedelics including psilocybin-producing fungi and our Field Trip Health division building centers for psychedelic therapies opening across North America and Europe along with the digital and technological tools that will enable massive scale, we help people from those in treatment to those seeking accelerated personal growth, with a simple, evidence-based way to heal and heighten engagement with the world.

Learn more at https://www.meetfieldtrip.com, https://www.fieldtriphealth.nl and https://www.fieldtriphealth.com.

Follow us on Twitter and Instagram: @fieldtriphealth

People interested in learning more about Field Trip Health’s Netherlands location and its truffle programs can do so by email (info.nl@fieldtriphealth.com) or online at www.fieldtriphealth.nl.

To receive company updates about Field Trip and to be added to the email distribution list, please sign up here.

For further information, contact Ronan Levy, Executive Chairman and a Director at Field Trip, at 1 (833) 833-1967.

Cautionary Note Regarding Forward-Looking Information.
This release includes forward-looking information within the meaning of Canadian securities laws regarding Field Trip and its business, which may include, but are not limited to, statements with respect to the listing of the common shares of Field Trip on the Canadian Securities Exchange, and the timing of such events. Often but not always, forward-looking information can be identified by the use of words such as “expect”, “intends”, “anticipated”, “believes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would” or “will” be taken, occur or be achieved. Such statements are based on the current expectations and views of future events of the management of Field Trip, and are based on assumptions and subject to risks and uncertainties. Although the management of Field Trip believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the companies, including risks regarding the COVID-19 epidemic, the medical clinic industry, market conditions, economic factors, management’s ability to manage and to operate the business and the equity markets generally. Although Field Trip has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Field Trip does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

Neither the Canadian Securities Exchange, nor its Regulation Services Provider, nor the OTC Markets have approved the contents of this release or accept responsibility for the adequacy or accuracy of this release.

Media contacts:
Paige Tatulli
Autumn Communications
212-206-9780
paiget@autumncommunications.com / fieldtrip@autumncommunications.com

Investor contacts:
Elizabeth Barker
KCSA Strategic Communications
212-896-1203
ebarker@kcsa.com

SOURCE Field Trip Health Ltd.

Posted on

Core One Labs Prepares First in Series of Patent Applications

Vancouver, British Columbia, Canada – February 10, 2021 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or “Core One Labs”) a biotechnology research and development life sciences enterprise focused on advancing psychedelic medicines to market, is pleased to announce preparations for filing a patent application encompassing its proprietary biosynthetic psilocybin production system.

With the completion of its initial studies, Core One’s subsidiary has assembled the necessary data from its research and development program on biosynthetic psilocybin production systems in order to commence the process of preparing and filing its first patent application with the United States Patent and Trademark Office (USPTO).

The initial filing is the first in a series of upcoming patent filings aimed at protecting valuable intellectual property that underpins the proprietary fermentative production process for active pharmaceutical ingredient (API) grade psilocybin.

The Company’s research team is continuing to develop new strategies to optimize expression of its proprietary DNA expression system that encodes the enzymes responsible for native psilocybin production in psychedelic mushrooms. Core One Labs intends to expand its patent portfolio with each milestone achievement as it works toward maximizing the output of psilocybin from its process development.

Joel Shacker, CEO of Core One Labs states, “We are proceeding towards the filing of several patent applications that will help safeguard our development efforts and protect the inherent value generation our work represents. The science that supports our extended research into biosynthesized psilocybin introduces multiple scenarios for the creation of different strains and potencies. These formulations hold promise for the manufacture of formulations offering enhanced and targeted efficacy. Our advanced production methods are designed to cut costs and production timelines which, combined with our scientific advancements, represent fundamental drivers propelling the company towards near term goals and opportunities. Protecting our valued intellectual property is critical to our strategy for success, and our patent efforts are of significant importance to the growth of the Company and the concurrent creation of shareholder value.”

About Core One Labs Inc.

Core One Labs is a biotechnology research and technology life sciences enterprise focused on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy. Core One Labs has developed a patent pending thin film oral strip (the “technology”) which dissolves instantly when placed in the mouth and delivers organic molecules in precise quantities to the bloodstream, maintaining excellent bioavailability. The Company intends to further develop and apply the technology to psychedelic compounds, such as psilocybin. Core One Labs also holds an interest in medical clinics which maintain a combined database of over 200,000 patients. Through these clinics, the integration of its intellectual property, R&D related to psychedelic treatments and novel drug therapies, the Company intends to obtain regulatory research approval for the advancement of psychedelic-derived treatments for mental health disorders.

Core One Labs Inc.

Joel Shacker

Chief Executive Officer

FOR MORE INFORMATION, PLEASE CONTACT:

info@core1labs.com

1-866-347-5058

Cautionary Disclaimer Statement:

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions, and expectations. They are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Such factors include, among other things: risks and uncertainties relating to the Company’s limited operating history and the need to comply with strict regulatory regulations.  Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.

In addition, psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act (Canada) and it is a criminal offence to possess substances under the Controlled Drugs and Substances Act (Canada) without a prescription or authorization. Health Canada has not approved psilocybin as a drug for any indication. Core One Labs does not have any direct or indirect involvement with illegal selling, production, or distribution of psychedelic substances in jurisdictions in which it operates. While Core One Labs believes psychedelic substances can be used to treat certain medical conditions, it does not advocate for the legalization of psychedelics substances for recreational use. Core One Labs does not deal with psychedelic substances, except within laboratory and clinical trial settings conducted within approved regulatory frameworks.

Posted on

Core One Labs Highlights Key Points From International Investor Call

Vancouver, British Columbia, Canada – February 10, 2021 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (“Core One” the “Company”) is pleased with the tremendous turnout on the International Investors’ Call held earlier today.  Core One’s Chairman, Dr. Robert E.W. Hancock and Chief Executive Officer, Joel Shacker provided participants an update on the Company’s current Intellectual Property and patent application process, cost to produce psilocybin, and the commercial viability.

Highlights

Intellectual Property and Patent Process

Dr. Hancock announced that the Company has assembled the necessary data for its research and development program on biosynthetic psilocybin production systems in order to commence the process of preparing and filing its first patent application with the United States Patent and Trademark Office.  The initial filing is the first in a series of upcoming patent filings aimed at protecting valuable intellectual property that underpins the proprietary fermentative production process for active pharmaceutical ingredient (API) grade psilocybin.

Vocan Psilocybin Production Cost

Vocan’s process engineers bacteria incorporating optimized biosynthetic genes from the psilocybe cubensis mushroom which will enable the bacteria to act as a biological factory and synthesize psilocybin that is highly cost-effective using simple building blocks.  The platform can make the active compounds that occur naturally by using a gene mimicry process and simple chemical modifications to enable the creation of bioidentical compounds, which can be proven to be more targeted and safer.

Comparison to Peers

Core One Lab’s has not identified any competitors that are currently developing biosynthesized psilocybin. There are other public companies producing psilocybin using different methods of production, such as synthetic psilocybin.  Typical cost of synthesizing a form of pure psilocybin that meets standards set by the US Food and Drug Administration’s Good Manufacturing Practice is anywhere from $7,000 – $10,000 per gram.

In the current psilocybin environment, we have not identified any companies that are able to produce pure psilocybin at one hundredth of the current cost.

Speaking about other companies in the psilocybin space Dr. Robert E. W. Hancock, Chairman of the Company stated, “You might consider them competitors, but in our case, we consider them to be potential clients.”

“We are very happy to see such great attendance on today’s call.  We are well positioned in psilocybin research and development of commercial products and look forward to providing future updates as they become available.” stated Joel Shacker CEO of the Company.

Shareholders and Investors are encouraged to visit our media section and view Dr. Robert E.W. Hancock’s insight into Vocan and Core One Labs.

Link: https://core1labs.com/media

About Core One Labs Inc.

Core One Labs Inc. is a research and technology company focused in life sciences and on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy.  The Company has developed a patent pending thin film oral strip (the “technology”) which dissolves instantly when placed in the mouth and delivers organic molecules in precise quantities to the bloodstream, maintaining excellent bioavailability. With this technology, the Company intends to further develop its IP technology to focus on delivering psychedelic molecules with an initial focus on psilocybin. Core One also holds an interest in walk-in medical clinics which maintain a database of over 200,000 patients combined. Through research and development in these clinics, including the integration of its intellectual property related to psychedelic treatments and novel drug therapies, the Company intends to work towards regulatory approval for research that advances psychedelic-derived treatments for mental health disorders.

Core One Labs Inc.

Joel Shacker

Chief Executive Officer

FOR MORE INFORMATION, PLEASE CONTACT:

info@core1labs.com

1-866-347-5058

Cautionary Disclaimer Statement:

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions, and expectations. They are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Such factors include, among other things: risks and uncertainties relating to the Company’s limited operating history and the need to comply with strict regulatory regulations.  Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.

In addition, psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act (Canada) and it is a criminal offence to possess substances under the Controlled Drugs and Substances Act (Canada) without a prescription or authorization. Health Canada has not approved psilocybin as a drug for any indication. Core One Labs does not have any direct or indirect involvement with illegal selling, production, or distribution of psychedelic substances in jurisdictions in which it operates. While Core One Labs believes psychedelic substances can be used to treat certain medical conditions, it does not advocate for the legalization of psychedelics substances for recreational use. Core One Labs does not deal with psychedelic substances, except within laboratory and clinical trial settings conducted within approved regulatory frameworks.

Posted on

Nova Mentis Psilocybin Approved for Shipment to Italy / Autism Treatment Study Underway

February 9, 2021 6:00 am Published by 

Novamentis

Vancouver, British Columbia – February 09, 2021 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) (“NOVA” or the “Company”) is pleased to announce that its proprietary drug psilocybin has been shipped to the laboratory of Dr. Viviana Trezza, Roma Tre University, Rome, Italy. NOVA was notified by its U.S. drug manufacturer that the required controlled substances export application had been approved by the U. S. Department of Justice Drug Enforcement Division (DEA).

The psilocybin will be evaluated in the ongoing prenatal valproic acid (VPA) model of autism spectrum disorder (ASD). In this model, which is well accepted by neuroscientists, pregnant rats are exposed to VPA and the resultant offspring have ASD behavioral symptoms (*Tartaglione, 2019). This animal model mimics the behavioral and social deficits seen in human ASD.

“Psychedelic research is currently undergoing a renaissance and we, at NOVA, are exuberant that the U.S. DEA has seen fit to approve the shipment of our proprietary psilocybin to Italy to be evaluated in ASD,” stated Marvin S. Hausman MD, Chairman, NOVA’s Scientific Advisory Board. “We look forward with great anticipation to be able to report that our drug ameliorated the social behavioral abnormalities in ASD. The therapeutic doses that will be established in the animal model will be extrapolated to a human study that is currently being designed.”

The shipped psilocybin, greater than 95 per cent purity, will be used to treat ASD offspring that have severe behavioral symptoms. This preclinical ASD diagnostic and treatment study began in January 2021 and fecal specimens are being collected to measure changes that occur in the microbial environment within the intestines of pregnant mothers and offspring after VPA exposure of the pregnant mothers.

A NOVA ASD Microbiome Diagnostic Index is being generated that will be potentially applicable to establish subsets of disorders to be treated with psychedelic compounds within the human spectrum called ASD. Animals with severe ASD behavioral symptoms are scheduled in the current study to undergo treatment with NOVA’s proprietary psilocybin. Comparisons will be made to control animals. The treatment phase will begin once ASD symptomatic pups have been weened away from the mother.

The study is designed to determine the efficacy of psilocybin in ASD and to establish therapeutic amounts of the drug to be used in an upcoming human trial. NOVA intends to file an Investigational New Drug (IND) application with U.S. and European regulatory agencies as soon as possible to begin Phase 1 human trials.

*Tartaglione, A.T., Schiavi, S., Calamandrei, G. and Trezza, V. 2019. Prenatal valproate in rodents as a tool to understand the neural underpinnings of social dysfunctions in autism spectrum disorder. Neuropharmacology 159,107477.

About Nova Mentis Life Science Corp.
Nova Mentis Life Science Corp. is a Canadian based biotechnology company that is focused on the emerging field of psychedelic medicine. The Company aims to become a global leader in this field by integrating the latest state-of-the-art medical and scientific technology into its drug development program. The goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as Autism Spectrum Disorder (ASD).

For further information on the Company, please visit https://www.novamentis.ca or email info@novamentis.ca.

On Behalf of the Board
Will Rascan, President & CEO
Nova Mentis Life Science Corp.
Phone: 778-819-0244
Toll Free: 1-833-542-5323
Twitter: @novamentislsc
Instagram: @novamentislsc
Facebook: @novamentislsc

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains statements that constitute “forward-looking statements.” Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause Nova Mentis Life Science’s actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “potential” and similar expressions, or that events or conditions “will,” “would,” “may,” “could” or “should” occur.

FacebookTwitterLinkedInEmailShare
Posted on

COMPASS Pathways expands its Discovery Center through new collaborations with world-leading scientists

COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has expanded its Discovery Center, through collaborations with world-leading laboratories at UC San Diego, School of Medicine, and Medical College of Wisconsin (MCW). Adam Halberstadt PhD, Associate Professor, Psychiatry, UC San Diego, and John D McCorvy PhD, Assistant Professor, Department of Cell Biology, Neurobiology and Anatomy, MCW, and their teams, will join Jason Wallach PhD, Assistant Professor of Pharmaceutical Sciences, University of the Sciences (Philadelphia), at the Discovery Center, a group of researchers working together, virtually.

The COMPASS Discovery Center was established in August 2020 through a sponsored research agreement between COMPASS and University of the Sciences. It is led by Jason Wallach’s laboratory at University of the Sciences and is now expanding its research network across the US, with Adam Halberstadt in San Diego, and John McCorvy in Wisconsin. The scientists intend to develop new, optimised psychedelic compounds to address unmet medical need. COMPASS will be the exclusive licensee for all new compounds generated.

Adam Halberstadt PhD is an expert on the behavioural neuropharmacology of psychedelics. He leads a team studying how psychedelics interact with serotonin systems and the implications for psychedelic therapy. Dr Halberstadt was the co-editor of the book Behavioural Neurobiology of Psychedelic Drugs and developed an efficient, automated head-twitch response preclinical assay that is now helping to expedite the screening of novel psychedelic compounds.

John McCorvy PhD is a 5-HT receptor pharmacologist and expert in G protein-coupled receptor (GPCR) signalling. His lab at MCW studies multiple aspects of GPCR signalling elicited by psychedelic, antipsychotic and antidepressant drugs. This work includes the importance of functional selectivity, whereby different drugs bind to the same receptor to cause different effects. He will be conducting detailed pharmacological characterisations of new compounds.

Jason Wallach PhD, who is leading the work at the Discovery Center, is a leading chemist and pharmacologist who studies a broad range of psychoactive compounds, including psychedelic and dissociative drugs. He said, “Psilocybin and other psychedelic compounds have shown promise for helping people suffering with mental health challenges, such as treatment-resistant depression. The Discovery Center is investigating whether similar compounds could have superior properties to psilocybin. We are looking for the next generation of compounds that might make a difference to patients. I’m honoured to be collaborating with Dr Halberstadt and Dr McCorvy, who bring increased breadth and depth of expertise to our research.”

Lars Wilde, Chief Business Officer and Co-founder, COMPASS Pathways, said, “This is a really exciting collaboration with three of the world’s most eminent scientists in psychedelic research. The Discovery Center will focus on preclinical research of novel psychedelic compounds addressing significant unmet need in a number of mental health indications. We believe that this will enable us to build a broad portfolio that will ultimately help patients and bring us closer to our vision of a world of mental wellbeing.”

About COMPASS Pathways

COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and we are currently conducting a phase IIb clinical trial of psilocybin therapy for TRD in 22 sites across Europe and North America. We are headquartered in London, UK, with offices in New York, US. Our vision is a world of mental wellbeing. www.compasspathways.com

Availability of other information about COMPASS Pathways

Investors and others should note that we communicate with our investors and the public using our website (www.compasspathways.com), our investor relations website (ir.compasspathways.com) and on social media (LinkedIn), including but not limited to investor presentations and investor fact sheets, US Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that we post on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in us to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include additional social media channels. The contents of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.


Forward-looking statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. In some cases, forward-looking statements can be identified by terminology such as “may”, “might”, “will”, “could”, “would”, “should”, “expect”, “intend”, “plan”, “objective”, “anticipate”, “believe”, “contemplate”, “estimate”, “predict”, “potential”, “continue” and “ongoing,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond COMPASS’s control and which could cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by these forward-looking statements.

These risks, uncertainties, and other factors include, among others, the risk that preclinical research and clinical development is lengthy and uncertain, and therefore our preclinical studies and clinical trials may be delayed or terminated, or may never advance to or in the clinic, the risk that results of preclinical studies may not be predictive of the results of clinical trials, and those risks and uncertainties described under the heading “Risk Factors” in COMPASS’s Prospectus filed with the US Securities and Exchange Commission (SEC) on 21 September 2020 and in subsequent filings made by COMPASS with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, COMPASS disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on COMPASS’s current expectations and speak only as of the date hereof.

Enquiries:

Media: Tracy Cheung, tracy@compasspathways.com, +44 7966 309024
Investors: Stephen Schultz, stephen.schultz@compasspathways.com, +1 401-290-7324

DailyMushroom

|

© 2021 DAILY MUSHROOM. All Rights Reserved